awmsg logo



insulin degludec (Tresiba®)


Reference No. 3158

Publication date:
21/10/2016


Appraisal information

insulin degludec (Tresiba®) 100 units/ml solution for injection
insulin degludec (Tresiba®) 200 units/ml solution for injection
insulin degludec (Tresiba®) Unspecified


Company: Novo Nordisk Ltd
BNF category: Endocrine system
NMG meeting date: 07/09/2016
AWMSG meeting date: 12/10/2016
   
   
Submission Type: Resubmission
Status: Recommended with restrictions
Advice No: 2816
Ministerial ratification: 20/10/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Insulin degludec (Tresiba®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adult patients where treatment with a basal insulin analogue is considered appropriate. Insulin degludec (Tresiba®) is not recommended for use within NHS Wales for the treatment of diabetes mellitus in adolescents and children from the age of 1 year.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download